Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TGM2 | P21980 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5116842 | 0.98 | HTT (0.72) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL667447 | 0.95 | HTT (0.72) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL9766289 | 0.94 | HTT (0.67) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL8371424 | 0.94 | HTT (0.67) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL234271 | 0.94 | HTT (0.70) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL17634037 | 0.94 | HTT (0.70) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL16692078 | 0.94 | HTT (0.70) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL887187 | 0.94 | HTT (0.70) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL31400174 | 0.94 | HTT (0.70) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL11441576 | 0.94 | HTT (0.70) | HTTLMNASMN1; SMN2TGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119101668-B | Mutant enzyme, fermentation production method thereof and application of mutant enzyme in preparation of buckwheat alkali | 华南师范大学 | 2025-05-09 | — | — | CN | claimed |
| CN-119101668-A | Mutant enzyme, fermentation production method thereof and application of mutant enzyme in preparation of buckwheat alkali | 华南师范大学 | 2024-12-10 | — | — | CN | claimed |
| CN-103214399-A | Preparation method of N-carbobenzoxy-3-amino propionaldehyde | UNIV EAST CHINA NORMAL | 2013-07-24 | — | — | CN | claimed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260049317-A1 | GalNAc Compound Containing Triazole Structure and Oligonucleotide Conjugate Thereof | BEIJING YOUCARE KECHUANG PHARMACEUTICAL TECH CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4696327-A1 | GALNAC COMPOUND CONTAINING TRIAZOLE STRUCTURE AND OLIGONUCLEOTIDE CONJUGATE THEREOF | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| EP-4640280-A2 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4384223-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-10-01 | — | — | EP | disclosed |
| WO-1995013817-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-26 | — | — | WO | disclosed |
| EP-0639586-A1 | Phosphonic acid derivatives, process for their preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 1995-02-22 | — | — | EP | disclosed |
| EP-0535967-A2 | Cyclohexapeptidyl bisamine compounds | MERCK & CO. INC. (US) | 1993-04-07 | — | — | EP | disclosed |
| US-5064819-A | Antidepressants, anxiolytic agents, GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| WO-1991002741-A1 | SUGAR ALCOHOL DERIVATIVES, A PROCESS FOR PREPARING 3-DEOXY-2-OCTULOSONIC ACID AND 3-DEOXY-2-HEPTULOSONIC ACID COMPOUNDS AND DERIVATIVES | RIJKSUNIVERSITEIT TE LEIDEN (NL) | 1991-03-07 | — | — | WO | disclosed |
| US-4954519-A | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents | GEORGIA TECH RESEARCH CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| US-4845242-A | ANTITUMOR | GEORGIA TECH RESEARCH CORPORATION (US) | 1989-07-04 | — | — | US | disclosed |
| US-4610983-A | N-acyl acidic amino acid diamide derivative, a salt thereof, and an anti-ulcer agent containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-09-09 | — | — | US | disclosed |
| US-4180565-A | ANTIBACTERIAL AGENTS, ANTIBIOTICS | SCHERING CORPORATION (US) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049317-A1 | GalNAc Compound Containing Triazole Structure and Oligonucleotide Conjugate Thereof | CSGALNACT1, B3GAT3, SLC10A1 | HTT 3613/4885LMNA 995/4885SMN1; SMN2 2509/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | HTT 2256/4885LMNA 4546/4885SMN1; SMN2 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.